Loading clinical trials...

Efficacy and Safety of Pimecrolimus for the Treatment of Vitiligo Vulgaris | Clinical Trials | Clareo Health

COMPLETEDPhase 2NCT00372307

Efficacy and Safety of Pimecrolimus for the Treatment of Vitiligo Vulgaris

Patients with vitiligo vulgaris are treated with Pimecrolimus twice a day during 6 months. After a baseline visit, patient returns for a control visit after 3 and 6 months of treatment. One reference ...

Lead sponsor: University Hospital, Ghent•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Related studies

UNKNOWNPhase 1

The Effect of Fractional Co2 Laser Either With Tacrolimus, Calcipotriol or NB-UVB in Stable Generalized Vitiligo

NCT03234673 · Vitiligo Vulgaris

COMPLETED

Questionnaire and Laboratory Data on Vitiligo Vulgaris

NCT01206374 · Vitiligo Vulgaris

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 28, 2007Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment26

Start dateMay 2004

Last updatedDec 28, 2007

Condition

Vitiligo Vulgaris

Locations shown

University Hospital Ghent

Ghent

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 28, 2007Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions